线粒体衍生肽在心血管疾病中的作用及其作为治疗靶点的潜力。
The Role of Mitochondria-Derived Peptides in Cardiovascular Diseases and Their Potential as Therapeutic Targets.
机构信息
Department of Clinical Diagnostics, Vitebsk State Academy of Veterinary Medicine [UO VGAVM], 7/11 Dovatora Str., 210026 Vitebsk, Belarus.
Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Institute of Human Morphology, 3 Tsyurupa Street, 117418 Moscow, Russia.
出版信息
Int J Mol Sci. 2021 Aug 16;22(16):8770. doi: 10.3390/ijms22168770.
Mitochondria-derived peptides (MDPs) are small peptides hidden in the mitochondrial DNA, maintaining mitochondrial function and protecting cells under different stresses. Currently, three types of MDPs have been identified: Humanin, MOTS-c and SHLP1-6. MDPs have demonstrated anti-apoptotic and anti-inflammatory activities, reactive oxygen species and oxidative stress-protecting properties both in vitro and in vivo. Recent research suggests that MDPs have a significant cardioprotective role, affecting CVDs (cardiovascular diseases) development and progression. CVDs are the leading cause of death globally; this term combines disorders of the blood vessels and heart. In this review, we focus on the recent progress in understanding the relationships between MDPs and the main cardiovascular risk factors (atherosclerosis, insulin resistance, hyperlipidaemia and ageing). We also will discuss the therapeutic application of MDPs, modified and synthetic MDPs, and their potential as novel biomarkers and therapeutic targets.
线粒体衍生肽 (MDPs) 是隐藏在线粒体 DNA 中的小肽，能够维持线粒体功能并在不同压力下保护细胞。目前，已经鉴定出三种类型的 MDPs：神经肽 Humanin、MOTS-c 和 SLP1-6。MDPs 在体外和体内均表现出抗凋亡和抗炎活性、活性氧和氧化应激保护特性。最近的研究表明，MDPs 具有重要的心脏保护作用，影响 CVDs（心血管疾病）的发展和进展。CVDs 是全球死亡的主要原因；该术语结合了血管和心脏的疾病。在这篇综述中，我们重点关注了最近在理解 MDPs 与主要心血管风险因素（动脉粥样硬化、胰岛素抵抗、高脂血症和衰老）之间关系方面的进展。我们还将讨论 MDPs、修饰和合成 MDPs 的治疗应用及其作为新型生物标志物和治疗靶点的潜力。
Zotero 插件